Advances in haematology and oncology 2011: hepatocellular carcinoma (HCC)

被引：0
作者：
Markus Peck-Radosavljevic
机构：
[1] Medical University of Vienna,Department of Medicine III, Division of Gastroenterology and Hepatology
来源：
memo - Magazine of European Medical Oncology | 2012年 / 5卷 / 2期
关键词：
Overall Survival; Sorafenib; Tace; Sorafenib Treatment; Sorafenib Group;
D O I：
10.1007/s12254-012-0009-0
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：161 / 162
页数：1
相关论文
共 14 条
  • [1] Bruix J(2011)Management of hepatocellular carcinoma: an update Hepatology. 53 1020-22
  • [2] Sherman M(2012)Clinical practice guidelines: management of hepatocellular carcinoma J Hepatol. 56 908-43
  • [3] Sangiovanni A(2010)The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis Gut. 59 638-44
  • [4] Manini MA(2012)Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial J Clin Oncol. 30 LBA154-undefined
  • [5] Iavarone M(undefined)undefined undefined undefined undefined-undefined
  • [6] Romeo R(undefined)undefined undefined undefined undefined-undefined
  • [7] Forzenigo LV(undefined)undefined undefined undefined undefined-undefined
  • [8] Fraquelli M(undefined)undefined undefined undefined undefined-undefined
  • [9] Lencioni R(undefined)undefined undefined undefined undefined-undefined
  • [10] Llovet JM(undefined)undefined undefined undefined undefined-undefined
12